We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Automatic Data ...

With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating Parkinson’s disease. The drug is the first ...

The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...

Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...

This morning, Hearst held its inaugural Female Force summit. Sponsored by AbbVie, Google News Initiative, and Trinet, the ...

This morning, Hearst held its inaugural Female Force summit. Sponsored by AbbVie, Google News Initiative, and Trinet, the ...

AbbVie also sells a continuous-delivery system for Parkinson's branded as Duopa that pumps a levodopa-carbidopa gel directly ...

After two previous failed attempts with the FDA, AbbVie now has one more offering in its lineup — a critical step as it ...

The Investment Committee debate the latest Calls Of The Day. How many of the best sci-fi movies ever made have you watched?

Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...